Celgene Co. (CELG) Short Interest Update
Celgene Co. (NASDAQ:CELG) was the target of a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 14,380,412 shares, a growth of 10.3% from the January 12th total of 13,038,301 shares. Based on an average daily volume of 9,042,197 shares, the days-to-cover ratio is currently 1.6 days. Approximately 1.8% of the shares of the company are sold short.
In other Celgene news, insider Mark J. Alles purchased 3,260 shares of the business’s stock in a transaction on Thursday, February 8th. The stock was acquired at an average price of $91.90 per share, with a total value of $299,594.00. Following the acquisition, the insider now directly owns 178,904 shares of the company’s stock, valued at approximately $16,441,277.60. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.95% of the company’s stock.
Hedge funds have recently bought and sold shares of the stock. Thompson Davis & CO. Inc. raised its stake in Celgene by 5.9% in the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 43 shares in the last quarter. Arcadia Investment Management Corp MI raised its stake in Celgene by 118.7% in the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 400 shares in the last quarter. Robecosam AG bought a new position in Celgene in the third quarter valued at about $114,000. Guidant Wealth Advisors bought a new position in Celgene in the third quarter valued at about $119,000. Finally, American Beacon Advisors Inc. bought a new position in Celgene in the fourth quarter valued at about $120,000. 78.10% of the stock is owned by institutional investors and hedge funds.
Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 EPS for the quarter, beating the Zacks’ consensus estimate of $1.78 by $0.09. The business had revenue of $3.48 billion during the quarter, compared to the consensus estimate of $3.46 billion. Celgene had a return on equity of 67.50% and a net margin of 22.38%. Celgene’s revenue for the quarter was up 16.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.61 earnings per share. equities analysts expect that Celgene will post 7.68 EPS for the current year.
Several brokerages have issued reports on CELG. Vetr raised Celgene from a “buy” rating to a “strong-buy” rating and set a $116.84 price target for the company in a report on Thursday, January 25th. Mizuho set a $128.00 price target on Celgene and gave the company a “buy” rating in a report on Tuesday, December 26th. William Blair reaffirmed an “outperform” rating on shares of Celgene in a report on Friday, October 20th. BTIG Research reaffirmed a “hold” rating on shares of Celgene in a report on Tuesday, January 23rd. Finally, BidaskClub raised Celgene from a “sell” rating to a “hold” rating in a report on Tuesday, December 12th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $130.35.
TRADEMARK VIOLATION WARNING: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.thecerbatgem.com/2018/02/14/celgene-co-celg-short-interest-update.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.